» Articles » PMID: 39473996

Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome

Abstract

Introduction: Fluid overload is a source of substantial morbidity for adults and children with nephrotic syndrome (NS). Preparation and Rationale for a Fluid Overload in Nephrotic Syndrome Clinical Outcomes Assessment Set for Drug Development (Prepare-NS, 5UG3FD007308) was funded by the US Food and Drug Administration to develop a core set of patient-reported and observer-reported (for young children) outcome measures of fluid overload for use in pharmaceutical trials across the lifespan.

Methods: The Prepare-NS study team developed the proposed context of use with input from stakeholders. We conducted a scoping review to assess the available literature on relevant patient- and observer-reported measures and performed secondary analyses of existing qualitative and quantitative data.

Results: The outcome set will aim to serve individuals 2 years of age and older with primary NS conditions (specifically focal segmental glomerulosclerosis, minimal change disease, IgM nephropathy, membranous nephropathy, and childhood-onset NS not biopsied). The existing literature describing patient-reported outcomes in NS largely relies on nonspecific measures of health-related quality of life; fluid overload has been associated with lower scores on these measures.

Conclusion: To address the gap in measure availability and fluid overload content, the Prepare-NS team has launched a set of qualitative studies for concept elicitation from the population of interest to inform development of new measures. The resulting measures subsequently will undergo psychometric evaluation and validation in a survey study.

References
1.
Terwee C, Peipert J, Chapman R, Lai J, Terluin B, Cella D . Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021; 30(10):2729-2754. PMC: 8481206. DOI: 10.1007/s11136-021-02925-y. View

2.
Mathias S, Vallow S, Gipson D, Thorneloe K, Sprecher D . Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire. Am J Kidney Dis. 2017; 70(4):532-540. DOI: 10.1053/j.ajkd.2017.04.023. View

3.
Carter S, Logeman C, Howell M, Cattran D, Lightstone L, Bagga A . Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney Int. 2021; 100(4):881-893. DOI: 10.1016/j.kint.2021.04.027. View

4.
Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

5.
Troost J, Waldo A, Carlozzi N, Murphy S, Modersitzki F, Trachtman H . The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. Clin Kidney J. 2020; 13(4):597-606. PMC: 7467600. DOI: 10.1093/ckj/sfz092. View